Prestige Biologics Co., Ltd. (KOSDAQ:334970)
South Korea · Delayed Price · Currency is KRW 2,760.00
-35.00 (-1.25%)
At close: Feb 27, 2026
Prestige Biologics Cash Flow Statement
Financials in millions KRW. Fiscal year is July - June.
Millions KRW. Fiscal year is Jul - Jun.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Jun '25 Jun 30, 2025 | Jun '24 Jun 30, 2024 | Jun '23 Jun 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -28,235 | -27,469 | -29,374 | -39,442 | -49,718 | -39,378 |
Depreciation & Amortization | 14,413 | 13,083 | 11,231 | 8,414 | 7,938 | 3,921 |
Loss (Gain) From Sale of Assets | 1.74 | 6.86 | -90.87 | -67.29 | -66.42 | - |
Asset Writedown & Restructuring Costs | - | - | - | 646.03 | 646.03 | - |
Stock-Based Compensation | - | - | -54.88 | 222.14 | 294.5 | 794.58 |
Other Operating Activities | -4,731 | -6,728 | -11,354 | 12,860 | 14,940 | 31,121 |
Change in Accounts Receivable | 2,413 | -51.97 | 674.2 | -1,063 | 1,175 | -1,167 |
Change in Inventory | -9,565 | -4,713 | 7,081 | -11,351 | -13,772 | -19,462 |
Change in Accounts Payable | 209.38 | 4,189 | 2,461 | 292.7 | -2,317 | 2,954 |
Change in Unearned Revenue | - | -309.87 | -5.22 | -663.92 | 147.48 | -307.31 |
Change in Other Net Operating Assets | 28,363 | 3,685 | 11,087 | 5,323 | 6,608 | -4,226 |
Operating Cash Flow | 2,870 | -18,308 | -8,345 | -24,830 | -34,124 | -25,750 |
Capital Expenditures | -7,650 | -5,226 | -8,522 | -35,435 | -84,642 | -97,392 |
Sale of Property, Plant & Equipment | 65.05 | 72.88 | 54 | 1,081 | 1,105 | - |
Sale (Purchase) of Intangibles | -916.1 | -430.06 | 350.02 | -107.47 | -147.41 | -619 |
Other Investing Activities | 6.5 | 24.82 | 191.11 | -19.29 | 19.23 | 101.18 |
Investing Cash Flow | -8,495 | -5,558 | -7,927 | -34,481 | -83,665 | -97,910 |
Long-Term Debt Issued | - | - | - | - | 96,172 | 74,685 |
Total Debt Issued | - | - | - | 56,500 | 96,172 | 74,685 |
Short-Term Debt Repaid | - | - | - | - | - | -2,700 |
Long-Term Debt Repaid | - | -95,031 | -913.51 | - | -59,912 | -3,736 |
Total Debt Repaid | -10,951 | -95,031 | -913.51 | -60,035 | -59,912 | -6,436 |
Net Debt Issued (Repaid) | -10,951 | -95,031 | -913.51 | -3,535 | 36,260 | 68,249 |
Issuance of Common Stock | 1,116 | 91,042 | 1,310 | 59,867 | 60,246 | 88,092 |
Other Financing Activities | -1.72 | -51.19 | -52.34 | -42.75 | -42.75 | -28.43 |
Financing Cash Flow | -9,837 | -4,041 | 344.5 | 56,289 | 96,463 | 156,312 |
Foreign Exchange Rate Adjustments | -27.48 | -18.82 | - | -472.96 | -65.68 | -118.89 |
Miscellaneous Cash Flow Adjustments | - | - | -0 | -0 | -0 | 0 |
Net Cash Flow | -15,490 | -27,926 | -15,928 | -3,494 | -21,392 | 32,533 |
Free Cash Flow | -4,780 | -23,534 | -16,867 | -60,265 | -118,767 | -123,142 |
Free Cash Flow Margin | -24.84% | -187.77% | -777.63% | -3451.94% | -763002.69% | -3816.18% |
Free Cash Flow Per Share | -58.24 | -319.14 | -275.63 | -1027.35 | -2295.00 | -2770.62 |
Cash Interest Paid | 2,278 | 4,686 | 3,355 | 4,831 | 4,764 | 818.02 |
Cash Income Tax Paid | - | - | - | 11.84 | -40.39 | -18.5 |
Levered Free Cash Flow | -5,451 | -33,288 | -27,812 | - | -98,250 | -127,117 |
Unlevered Free Cash Flow | -1,033 | -27,829 | -20,456 | - | -95,795 | -126,640 |
Change in Working Capital | 21,421 | 2,799 | 21,297 | -7,462 | -8,158 | -22,208 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.